Glioblastoma, an aggressive brain cancer, has left patients with limited treatment options for far too long. But a groundbreaking clinical trial, known as 5G, is here to change that.
Brain tumors are devastating, not only affecting a person's physical abilities but also their very identity. Despite remarkable progress in understanding brain and central nervous system cancers, treatment advancements have lagged, especially in drug therapies. This disparity is evident when comparing it to other cancer types, like breast cancer, which has seen numerous new treatments approved in recent years.
A pivotal Cancer Research UK-funded trial is now accelerating brain tumor drug discovery in the UK. By swiftly identifying promising drug candidates, this trial aims to offer new hope to patients.
The slow progress in glioblastoma treatment has been attributed to a series of 'nihilisms,' according to Richard Mair, a consultant neurosurgeon. Initially, there was a reluctance among neurosurgeons to perform proper operations, a sentiment that has largely faded but still persists. This was accompanied by 'therapeutic nihilism,' where researchers believed developing drugs for brain tumors was too challenging due to the blood-brain barrier. Additionally, 'pharmaceutical nihilism' emerged, with drug manufacturers hesitant to trial existing drugs for brain cancer patients due to their fragility.
Brain tumors are relatively rare compared to other cancer types, leading to 'financial nihilism' - the belief that there aren't enough patients to justify the cost of developing drugs. Recruiting enough participants for trials is also a challenge, as seen in the case of glioblastoma, which affects a smaller population.
Beyond these obstacles, the complexity of the brain and the tumors within it pose fundamental challenges. Glioblastoma involves a tangled web of genetic, molecular, and environmental changes, making it difficult to develop effective treatments. The lack of good lab models that accurately reflect brain tumor behavior has been a major hurdle. Additionally, the blood-brain barrier has often been seen as an impediment to drug delivery, but growing evidence suggests that it may not be as much of a barrier as once thought.
Despite these challenges, there is a growing body of evidence that various treatments, including standard chemotherapy, targeted therapies, and antibody-based drugs, can effectively reach brain tumors. Yet, people with primary brain tumors are still routinely excluded from early clinical trials, missing out on potential treatment opportunities.
Several years ago, Richard Mair was focused on utilizing new technologies like next-generation sequencing to understand brain cancer's molecular makeup. The Precision Brain Tumour Programme, established with funding from the Minderoo Foundation, aimed to speed up the process of returning results to clinicians. By establishing close links with the hospital's genomic laboratory hub, Mair's team could carry out tumor analyses within 20 days.
After sequencing over 300 patients' tumors, it became clear that while it didn't dramatically change diagnoses, it did suggest potential weaknesses in some tumors that could be targeted. However, Mair and his team faced another issue - there wasn't a good way to refer patients into clinical trials.
Mair's collaboration with Juanita Lopez, an expert in clinical trial design, led to the development of the next-Generation aGile Genomically Guided Glioma platform trial, or '5G.' This precision adaptive platform trial uses specific drug/biomarker pairings for each arm, a departure from traditional brain cancer trials. It allows for iteration, flexibility with drug combinations, and the ability to start giving promising drugs to patients right after initial surgery and radiotherapy.
Since its launch, 5G has initiated several sub-trials, testing different therapy combinations in people with different tumor mutations. One notable feature is that these are existing therapies proven safe and effective in other cancer types, making it a 'first-in-brain' trial.
Mair emphasizes that this trial is about offering hope to patients with brain tumors, who are often vulnerable to charlatans and snake oil salesmen. The goal is to provide a viable alternative to standard care, which ultimately fails patients. Empowering patients to make decisions about their care, as advocated by the late Tessa Jowell, is a driving force behind this initiative.
The first preliminary results are expected soon, and Mair believes that this trial will make a significant impact on the treatment landscape for glioblastoma patients.
